Tivorsan names new CEO

JAMES E. CONNOLLY has been named CEO of Tivorsan Pharmaceuticals Inc. in Providence. / COURTESY TIVORSAN PHARMACEUTICALS INC.
JAMES E. CONNOLLY has been named CEO of Tivorsan Pharmaceuticals Inc. in Providence. / COURTESY TIVORSAN PHARMACEUTICALS INC.

PROVIDENCE – Tivorsan Pharmaceuticals Inc. has named James E. Connolly CEO.
The biotechnology company, which focuses on treating Duchenne Muscular Dystrophy and other neuromuscular disorders, also said that Connolly will serve as a member of its board. Connolly has worked for more than 25 years in the pharmaceutical, biotechnology and nonprofit sectors in leadership roles, according to a company news release.
“I’m excited about joining Tivorsan, a company that has the potential to become a significant player in the arena of neuromuscular disorders,” Connolly said in a statement. “Leading Tivorsan will enable me to apply all that I’ve learned during my career in the pharmaceutical and biotechnology industries to help bring much-needed treatments to patients and their families living with Duchenne, Becker and congenital muscular dystrophies, as well as other neuromuscular disorders.”
Said Dr. John P. Nicholson, board chairman, “Throughout his extensive career, Jim Connolly has demonstrated strong leadership, management and business-building expertise, coupled with a passion for addressing unmet health needs. This is the exact blend of skills necessary to successfully transition Tivorsan to a development stage organization and advance our compound, recombinant human biglycan, into clinical trials with its initial indication for Duchenne Muscular Dystrophy in the near future.”
Nicholson said Joel Braunstein had been acting as CEO and will continue to serve on the board.
Connolly operated his own firm, JE Connolly Consulting, providing consulting and advisory services to pharmaceutical, biotechnology and investment organizations, before joining Tivorsan.
Previously, Connolly served as president and CEO of Aeras, a Rockville, Md.-based nonprofit global biotechnology organization working to develop tuberculosis vaccines.
Connolly continues to serve on the board of directors for Aeras, as well as on the boards of PaxVax and Vaxess Technologies.

No posts to display